All In Biotech

Drug Trial Radar · NCT05201079

Primary or Recurrent Clostridioides Difficile Infection Treatment With Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin

A Randomised, Controlled, Open-label Phase III Clinical Trial in Patients With Primary or Recurrent Clostridioides Difficile (CD) Infection, to Evaluate the Efficacy and Safety of Capsules of Lyophilised Faecal Microbiota vs Fidaxomicin.

Last checked: Nov 19, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

93

Actual

Start

Oct 29, 2021

Primary completion

Nov 15, 2023

Study completion Nov 15, 2023

Sponsor

Sponsor type
Industry
First posted
Jan 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with microbiota alterations developed after being exposed to antibiotics are especially susceptible to Clostridioides difficile infections (CDI). The incidence and severity of CDI has increased in recent years and CDI recurrences (r-CDI) due to the appearance of new episodes in patients with a previous cured CDI, represent a serious and complex clinical issue. Although antibiotics are the recommended therapy for the first episode of CDI, treatment with oral vancomycin and/or metronidazole often results in significant treatment failure. In addition, the treatment of r-CDI is not adequately standardized, and although the most widely used treatment is the administration of fidaxomicin and bezlotoxumab, its efficacy in patients who already have r-CDI is not proven. In the late years, Fecal Microbiota Transfer (FMT) has emerged as the preferred non-pharmacological treatment to manage CDI with multiple recurrences and recent clinical trials have evaluated its potential efficacy and safety in the treatment of patients with primary CD infection. The objective of this study is to assess the efficacy and safety of the MBK-01 medication, consisting of heterologous lyophilized fecal microbiota capsules coming from healthy donors in comparison to the treatment with fidaxomicin, in 92 patients with primary or r-CDI.

Conditions

  • Recurrent Clostridium Difficile Infection
  • Primary Clostridium Difficile Infection

Interventions

  • MBK-01Biological

    A single dose of 4 capsules of MBK-01 (heterologous lyophilized fecal microbiota coming from healthy donors) orally.

  • FidaxomicinDrug

    Oral administration of 200mg/12 hours of fidaxomicin for 10 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Global Absence of Diarrhea Due to Clostridiodes Difficile 8 Weeks After the Start of the TreatmentTime frame: 8 weeks after the start of the treatment
  2. Absence of Diarrhea: Number of Episodes of Diarrhea (3 or More Stools/24 Hours) 72 Hours After the Start of the TreatmentTime frame: 72 hours after the start of the treatment
  3. Absence of Diarrhea: Number of Episodes of Diarrhea (3 or More Stools/24 Hours) 3 Weeks After the Start of the TreatmentTime frame: 3 weeks after the start of the treatment
  4. Absence of Diarrhea: Number of Episodes of Diarrhea (3 or More Stools/24 Hours) 3 Months After the Start of the TreatmentTime frame: 3 months after the start of the treatment
  5. Absence of Diarrhea: Number of Episodes of Diarrhea (3 or More Stools/24 Hours) 6 Months After the Start of the TreatmentTime frame: 6 months after the start of the treatment

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital General Universitario de Alicante

    Alicante, Spain

  • Hospital Universitario de Cruces

    Barakaldo, Spain

  • Hospital Quirónsalud Barcelona

    Barcelona, Spain

  • Hospital Clínic de Barcelona

    Barcelona, Spain

  • Hospital Universitario de Bellvitge

    Barcelona, Spain

  • Hospital Universitario de Basurto

    Bilbao, Spain

  • Hospital Universitario Reina Sofía

    Córdoba, Spain

  • Hospital Universitario de Donostia

    Donostia / San Sebastian, Spain

  • Hospital Josep Trueta de Gerona

    Girona, Spain

  • Hospital San Pedro

    Logroño, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario Puerta de Hierro

    Madrid, Spain

  • Hospital Universitario Quirónsalud Madrid

    Madrid, Spain

  • Hospital Universitario Son Espases

    Palma de Mallorca, Spain

  • Hospital Universitario y Politécnico La Fe

    Valencia, Spain

  • Hospital Universitario de Araba

    Vitoria-Gasteiz, Spain

  • Hospital Clínico Universitario Lozano Blesa

    Zaragoza, Spain

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.